Pathologic Response Evaluation in Neoadjuvant-Treated Lung Cancer

Major pathologic response (MPR) and pathologic complete response (pCR) are increasingly being used in non-small cell lung carcinoma neoadjuvant clinical trials as an early endpoint of survival. MPR for all histologic types of lung cancer is ≤ 10% of viable tumor, while pCR requires no viable tumor....

Full description

Saved in:
Bibliographic Details
Published inSurgical pathology clinics Vol. 17; no. 2; p. 287
Main Author Dacic, Sanja
Format Journal Article
LanguageEnglish
Published United States 01.06.2024
Subjects
Carcinoma, Non-Small-Cell Lung - drug therapy
Carcinoma, Non-Small-Cell Lung - pathology
Humans
Lung Neoplasms - drug therapy
Lung Neoplasms - pathology
Neoadjuvant Therapy
Pneumonectomy
Treatment Outcome
Neoadjuvant
Resection
Pathologic response
Lung cancer
Online AccessGet more information

Cover

More Information
Summary:Major pathologic response (MPR) and pathologic complete response (pCR) are increasingly being used in non-small cell lung carcinoma neoadjuvant clinical trials as an early endpoint of survival. MPR for all histologic types of lung cancer is ≤ 10% of viable tumor, while pCR requires no viable tumor. The International Association for the Study of Lung Cancer multidisciplinary recommendation for the assessment of response in surgically resected lung carcinomas after neoadjuvant therapy was the first attempt to standardize grossing processing and microscopic evaluation.
ISSN:1875-9157
DOI:10.1016/j.path.2023.11.010